Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)

Inclusion criteria

• Patients, male or female of any race or ethnicity, 18 years of age or older, diagnosed with ocular hypertension or open-angle glaucoma (with or without pseudoexfoliative or pigmentary dispersion component).
• Stable use of Latanoprost 0.005% for a minimum of 30 days prior to screening visit.
• VA of 20/200 or better in either eye
• Pachymetry of 600 microns or less
• Visual Field within 6 months of screening visit
• Patients who use contact lenses are allowed to participate provided that they will remove lenses 15 minutes before dosing
• Patients who satisfy all informed consent requirements may be included in the study.

Exclusion criteria

• Females of childbearing potential (those who are not surgically sterile, postmenopausal or using a reliable birth control method) will be excluded from the study.
• Any allergic component or contraindication to the study medications
• Pachymetry of 600 microns or greater
• Systemic corticosteroids not on a stable regimen within 30 days of screening visit.
• Any concurrent topical agents that can not be discontinued during the course of the trial (natural tears are acceptable)
• Significant ocular surface abnormalities
• Patients with any form of glaucoma other than ocular hypertension or open-angle glaucoma
• Patients who have been on an investigational therapy within 30 days prior to screening visit
• History of ocular trauma within the past 3 months
• Intraocular surgery within the past 3 months
• Ocular laser surgery within the past 3 months
• Any abnormality preventing reliable applanation tonometry of either eye
• VA of 20/200 or greater in either eye
• History or evidence of clinically significant illness or conditions which would make the patient, in the opinion of the investigator, not suitable for the study